SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator: Inoviorulez
Search This Board:
Last Post: 10/23/2016 3:46:40 AM - Followers: 138 - Board type: Free - Posts Today: 1

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.


RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.


This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...


June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#3640  Sticky Note Rxi Pharmaceuticals (RXII) Research Report 2016 Inoviorulez 06/19/16 09:15:20 AM
#4047   s-1: here comes dilution. Get out now and alexander77 10/23/16 03:46:40 AM
#4046   meh.. sidslids 10/21/16 03:44:20 PM
#4045   meh. sidslids 10/20/16 04:39:26 PM
#4044   I wouldn't call that news. It is an Titan V 10/20/16 04:12:03 PM
#4043   Titan V 10/20/16 04:11:30 PM
#4042   The one by GEERT which you posted the rdsrich 10/20/16 04:02:46 PM
#4041   Sorry, which news release? Titan V 10/20/16 03:41:18 PM
#4040   I didn't mean the post, I meant the rdsrich 10/20/16 03:37:12 PM
#4039   No, I posted this way after today's run Titan V 10/20/16 03:17:15 PM
#4038   Is this what is moving the stock? rdsrich 10/20/16 03:12:25 PM
#4037   Age-Related Macular Degeneration: On the Rise as Baby Titan V 10/20/16 12:12:08 PM
#4036   Time for Geert to turn this around or leave. microchips 10/19/16 05:22:55 PM
#4035   meh. sidslids 10/19/16 03:05:00 PM
#4033   Keeping a lid on at a dollar so The Other Guy 10/19/16 12:31:49 PM
#4032   Interesting trading day on this one. It looks microchips 10/19/16 11:32:24 AM
#4031   When everyone is selling is when i BUY rdsrich 10/19/16 10:15:18 AM
#4030   3a) initiate a slam campaign on social media The Other Guy 10/19/16 10:08:15 AM
#4029   Another smart post. I like this message rdsrich 10/18/16 06:37:14 PM
#4028   Thank you, makes sense. rdsrich 10/18/16 06:34:10 PM
#4027   "Stock is getting pummelled by shorts IMHO" sabaidii2 10/18/16 04:37:54 PM
#4026   When you announce buying a company when you Titan V 10/18/16 04:37:44 PM
#4025   Stock is getting pummelled by shorts IMHO rdsrich 10/18/16 04:21:49 PM
#4024   SORRY WRONG STOCK rdsrich 10/18/16 04:19:29 PM
#4023   SORRY GUYS, I got mixed up with another stock! rdsrich 10/18/16 04:18:59 PM
#4022   Are you sure this is the reply from BioPharma 10/18/16 04:16:22 PM
#4021   Q3 '16 results means earnings results which is Titan V 10/18/16 04:15:54 PM
#4020   They are selling stock to buy out the rdsrich 10/18/16 04:15:35 PM
#4019   Here is a reply from IR: rdsrich 10/18/16 04:04:36 PM
#4018   "Piddly" was auto-corrected to "puddly." Puddly is The Other Guy 10/18/16 01:48:25 PM
#4017   1) I'm not confident that dilution is even sabaidii2 10/18/16 01:27:59 PM
#4016   They will not close the doors. Worst The Other Guy 10/18/16 01:18:40 PM
#4015   Geert has made similar inflammatory remarks in the shtsandwich 10/18/16 01:14:15 PM
#4014   Geert also mentioned that now was a good sabaidii2 10/18/16 01:04:28 PM
#4013   Another point from the presentation is the company The Other Guy 10/18/16 12:59:01 PM
#4012   Geert confirmed the other RNAi platforms are still The Other Guy 10/18/16 12:47:08 PM
#4011   It is already a penny stock but another InternetForumUser 10/18/16 11:53:32 AM
#4010   Down every day since RXi announced buying MirImmune. BioPharma 10/18/16 10:42:15 AM
#4009   If IR response to you, please post response here. BioPharma 10/17/16 08:37:57 PM
#4008   Keep in mind, it's not a cash buyout The Other Guy 10/17/16 05:32:58 PM
#4007   Agree, MirImmune will not accept current 1 million BioPharma 10/17/16 05:09:24 PM
#4006   Very first post (ever) by a brand new sabaidii2 10/17/16 04:35:47 PM
#4005   How much cash? It cannot be much The Other Guy 10/17/16 04:04:08 PM
#4004   The company they are buying is private, they rdsrich 10/17/16 03:58:19 PM
#4003   Stock went from $5 pre split 2 $0.11 Hypocrates 10/17/16 03:32:30 PM
#4002   Right now this deal makes no sense. How The Other Guy 10/17/16 01:18:41 PM
#4001   Wow looks like another Reverse Split is on InternetForumUser 10/17/16 12:30:14 PM
#4000   No dilution? This thing has been diluted to microchips 10/14/16 01:33:25 PM
#3999   I hope Geert can find a way not sabaidii2 10/14/16 12:38:47 PM
#3998   If Geert is status quo on Tuesday with The Other Guy 10/14/16 12:37:19 PM
#3997   It could be the case. Maybe sooner The Other Guy 10/14/16 12:22:40 PM